Cavender Matthew A, Rao Sunil V, Ohman E Magnus
Duke University Medical Center, Department of Medicine, Box 31110 Durham, NC 27710, USA.
Expert Opin Pharmacother. 2008 Aug;9(11):1869-83. doi: 10.1517/14656566.9.11.1869.
Guidelines for the management of high-risk non ST-segment elevation acute coronary syndrome (NSTE ACS) recommend antithrombotic and antiplatelet therapy combined with an early invasive strategy. While this strategy reduces ischemic complications, it places patients at risk for bleeding complications.
We sought to provide a narrative review of the risk factors for bleeding, risks associated with bleeding and strategies to prevent bleeding complications.
A comprehensive literature review was performed to identify relevant evidence.
RESULTS/CONCLUSIONS: Bleeding complications in NSTE ACS are associated with adverse events and higher mortality. Prevention of bleeding complications can be achieved through judicious dosing of medications, the use of antithrombotic agents associated with a lower bleeding risk and use of the radial artery approach in patients requiring coronary intervention. Future work should focus on delineating the mechanisms underlying the bleeding-mortality relationship and developing a better understanding of the tradeoff between efficacy and safety.
高危非ST段抬高型急性冠状动脉综合征(NSTE ACS)管理指南推荐抗栓和抗血小板治疗联合早期侵入性策略。虽然该策略可降低缺血性并发症,但会使患者面临出血并发症风险。
我们试图对出血危险因素、与出血相关的风险以及预防出血并发症的策略进行叙述性综述。
进行全面的文献综述以识别相关证据。
结果/结论:NSTE ACS中的出血并发症与不良事件和更高的死亡率相关。通过合理用药、使用出血风险较低的抗栓药物以及对需要冠状动脉介入治疗的患者采用桡动脉途径,可预防出血并发症。未来的工作应侧重于阐明出血与死亡率关系的潜在机制,并更好地理解疗效与安全性之间的权衡。